HC Wainwright restated their buy rating on shares of Ocugen (NASDAQ:OCGN - Free Report) in a research report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $7.00 target price on the stock.
Separately, Maxim Group initiated coverage on Ocugen in a report on Tuesday, October 15th. They issued a "buy" rating and a $4.00 target price on the stock.
View Our Latest Stock Analysis on OCGN
Ocugen Price Performance
Shares of OCGN traded down $0.02 during trading hours on Wednesday, hitting $0.91. 2,022,382 shares of the company were exchanged, compared to its average volume of 6,275,701. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.09. Ocugen has a fifty-two week low of $0.35 and a fifty-two week high of $2.11. The company has a market cap of $234.22 million, a price-to-earnings ratio of -3.64 and a beta of 3.70. The firm's fifty day moving average is $1.11 and its 200 day moving average is $1.40.
Ocugen (NASDAQ:OCGN - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.02. The firm had revenue of $1.14 million during the quarter. During the same quarter in the prior year, the company posted ($0.10) earnings per share. On average, equities analysts anticipate that Ocugen will post -0.2 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Ocugen
A number of institutional investors have recently added to or reduced their stakes in OCGN. Xponance Inc. acquired a new position in shares of Ocugen during the second quarter worth $25,000. Baader Bank Aktiengesellschaft acquired a new position in Ocugen in the 2nd quarter worth about $35,000. Victory Capital Management Inc. bought a new position in Ocugen in the second quarter valued at about $51,000. Headlands Technologies LLC acquired a new stake in shares of Ocugen during the first quarter valued at about $66,000. Finally, Daiwa Securities Group Inc. bought a new stake in shares of Ocugen during the second quarter worth about $67,000. 10.27% of the stock is currently owned by institutional investors and hedge funds.
Ocugen Company Profile
(
Get Free Report)
Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Featured Articles
Before you consider Ocugen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ocugen wasn't on the list.
While Ocugen currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
